Although reductions in waist circumference, a marker of central adiposity, were associated with improved outcomes and explained part of the treatment effect, most of the cardiovascular benefit appeared unrelated to measurable changes in adiposity
At Healthon, we provide the expert support you need to make an informed decision with confidence
There is still so much misinformation in our society that many patients and even healthcare providers still believe that obesity can be permanently reversed with enough willpower and counting your calories in versus out, says Michael Glickman, MD, the founder and CEO at Revolution Medicine
What I saw in the available data is that retatrutide actually improved liver fat in people with metabolic dysfunction-associated steatotic liver disease (MASLD)
Who should not take GLP-1s GLP-1s in all forms are unsuitable for people who: are pregnant or breastfeeding do not meet the eligibility criteria have a family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Medical Perspective Patients with needle phobia, a preference for pill-based routines, or good adherence to oral administration guidelines may be better suited to oral GLP-1 formulations like semaglutide (Rybelsus, Wegovy), which can enhance treatment acceptance and potentially offer strong glycemic or weight control
SeekPeptides has compiled the most comprehensive storage reference available, drawing from pharmaceutical stability data, compounding pharmacy guidelines, and real-world handling experience to give you everything you need in one place